Grifols is a pioneer in plasma science that develops plasma into essential medicines used to treat rare, chronic and life-threatening conditions. Eric Björnestål, general manager for the Nordic region, explains how the company is leveraging its knowledge of the public tender process to continue to grow in the region, highlights Sweden’s unique assets like the quality registries, and discusses his long-term vision for the affiliate.
Sweden has, in some cases, not focused on the lowest price per unit only, but on the most economically advantageous tender, taking several parameters into consideration; we welcome this approach
